Clinical Risk
CHA₂DS₂-VASc (Stroke Risk in AFib)
Estimates annual stroke risk in patients with non-valvular atrial fibrillation using the CHA₂DS₂-VASc score (Lip 2010).
About CHA₂DS₂-VASc (Stroke Risk in AFib)
CHA₂DS₂-VASc (Stroke Risk in Atrial Fibrillation)
The CHA₂DS₂-VASc score, introduced by Lip and colleagues in 2010 in Chest, extended the earlier CHADS₂ score by adding vascular disease, age 65-74, and female sex as additional stroke risk factors in patients with non-valvular atrial fibrillation. The expanded score is now the standard stroke risk stratification tool in the 2023 ACC/AHA/ACCP/HRS AFib guideline, the European Society of Cardiology AFib guideline, and the Canadian Cardiovascular Society AFib guideline. Its principal value is to identify patients at sufficiently low stroke risk that anticoagulation is not warranted, while ensuring that all patients who benefit from anticoagulation receive it.What the calculator measures
The CHA₂DS₂-VASc score is an integer from 0 to 9 that estimates annual stroke risk in patients with non-valvular atrial fibrillation. The annual stroke risk for a score of 0 is approximately 0.2% in men (in whom female sex adds no risk without other risk factors); for a score of 2, approximately 2.2%; for a score of 4, approximately 4-5%; and for a score of 6 or higher, approximately 9-10%. The principal use is to decide whether to initiate oral anticoagulation.How the formula works
The CHA₂DS₂-VASc acronym is the score:- C. Congestive heart failure (1 point)
- H. Hypertension (1 point)
- A₂. Age ≥75 years (2 points)
- D. Diabetes (1 point)
- S₂. Prior stroke, TIA, or thromboembolism (2 points)
- V. Vascular disease (prior MI, PAD, or aortic plaque) (1 point)
- A. Age 65-74 (1 point)
- Sc. Female sex (1 point)
Interpretation
The 2023 ACC/AHA/ACCP/HRS AFib guideline recommends:- Score 0 in men or 1 in women: Oral anticoagulation is not recommended (annual stroke risk <1% is below the threshold at which anticoagulation benefit outweighs bleeding risk).
- Score 1 in men or 2 in women: Oral anticoagulation may be considered; the decision should be individualized based on patient preferences, bleeding risk, and other clinical factors.
- Score ≥2 in men or ≥3 in women: Oral anticoagulation is recommended.
Clinical use
The CHA₂DS₂-VASc score is used at the time of AFib diagnosis (or at each clinical encounter) to determine the indication for oral anticoagulation. The guideline-recommended threshold for anticoagulation is a score of 2 or higher in men or 3 or higher in women. Direct oral anticoagulants (DOACs, apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin in most patients with non-valvular AFib because of lower bleeding risk (particularly intracranial hemorrhage), similar or better efficacy, and convenience (no routine INR monitoring). Warfarin remains preferred in patients with mechanical heart valves or moderate-to-severe mitral stenosis.Limitations
The CHA₂DS₂-VASc score has several limitations. First, it does not capture all stroke risk factors in AFib, it excludes kidney dysfunction, sleep apnea, inflammation, and echocardiographic markers (left atrial size, left ventricular function). Second, the female sex criterion is a 'risk modifier' rather than an independent risk factor: a score of 1 (female sex alone) does not warrant anticoagulation. Third, the score was derived and validated predominantly in white European and North American populations; performance in other populations is less well characterized. Fourth, the score does not account for AFib burden (paroxysmal vs persistent vs permanent), modern data suggest that higher AFib burden is associated with higher stroke risk independent of CHA₂DS₂-VASc. Fifth, the score does not incorporate bleeding risk; the HAS-BLED or ORBIT score should be used in parallel to assess bleeding risk.Comparison with CHADS₂
The earlier CHADS₂ score (Gage 2001) included only congestive heart failure, hypertension, age ≥75, diabetes, and prior stroke/TIA. The CHA₂DS₂-VASc extension added vascular disease, age 65-74, and female sex. The expanded score classifies more patients as intermediate or high risk, which is appropriate because CHADS₂ underestimated stroke risk in patients with 0-1 scores. The 2023 ACC/AHA/ACCP/HRS guideline explicitly prefers CHA₂DS₂-VASc over CHADS₂ for stroke risk stratification.How to use the result
A CHA₂DS₂-VASc score of 3 (in a man) corresponds to approximately 3-5% annual stroke risk without anticoagulation. With anticoagulation, this risk is reduced by approximately two-thirds (relative risk reduction ~64% for warfarin, ~70% for DOACs). The absolute risk reduction is therefore approximately 2-3% per year, meaning that approximately 30-50 patients need to be treated for 1 year to prevent one stroke. This benefit must be weighed against the bleeding risk (assessed by HAS-BLED or ORBIT) and patient preferences.
Editorial and formula review
Formula sources, population limits, and references for this clinical risk calculator are documented in our public methodology. Read the methodology · Medical disclaimer
Frequently asked questions
No. The 2023 ACC/AHA/ACCP/HRS guideline explicitly states that female sex is a risk modifier rather than an independent risk factor. A score of 1 due to female sex alone does not warrant anticoagulation. The threshold for women is effectively 2 or higher (i.e. female sex plus at least one other risk factor).
CHA₂DS₂-VASc is the preferred score in the 2023 AFib guideline. It captures more risk factors (vascular disease, age 65-74, female sex) than CHADS₂ and is more sensitive at the low end of the risk spectrum. CHADS₂ was used previously but has been largely superseded; CHADS₂ can still be useful for patients with missing data on the additional CHA₂DS₂-VASc components.
Yes, paroxysmal AFib carries similar stroke risk as persistent or permanent AFib at the same CHA₂DS₂-VASc score. The decision to anticoagulate should be based on the CHA₂DS₂-VASc score, not on the AFib pattern. Modern data suggest that AFib burden (the proportion of time in AFib) may modify risk, but the threshold for clinical action remains the CHA₂DS₂-VASc score.